To expand this analysis, we took advantage of the data reported by Gui et al. [14] which includes mainy MIBC: in their series 13/97 tumors had a mutation in ARID1A and 9/97 tumors had a mutation in FGFR3; 1/97 had a mutation in both genes supporting a lack of association between both genetic alterations in this tumor subgroup. The gene discussed is FGFR3; the disease is neoplasm.